vs
ASP Isotopes Inc.（ASPI）与Verastem, Inc.（VSTM）财务数据对比。点击上方公司名可切换其他公司
ASP Isotopes Inc.的季度营收约是Verastem, Inc.的1.5倍（$16.7M vs $11.2M）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
Verastem, Inc.以Verastem Oncology品牌开展业务，是一家总部位于美国马萨诸塞州波士顿的制药企业，专注于开发抗癌治疗药物，该公司成立于波士顿，同时是纳斯达克生物技术指数成分股之一。
ASPI vs VSTM — 直观对比
营收规模更大
ASPI
是对方的1.5倍
$11.2M
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $11.2M |
| 净利润 | — | $-98.5M |
| 毛利率 | 12.5% | — |
| 营业利润率 | — | -362.2% |
| 净利率 | — | -876.3% |
| 营收同比 | 1295.7% | — |
| 净利润同比 | -586.8% | -311.1% |
| 每股收益（稀释后） | — | $-1.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPIVSTM
| Q4 25 | $16.7M | — | ||
| Q3 25 | $4.9M | $11.2M | ||
| Q2 25 | — | $2.1M | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $10.0M |
净利润ASPIVSTM
| Q4 25 | — | — | ||
| Q3 25 | $-12.9M | $-98.5M | ||
| Q2 25 | — | $-25.9M | ||
| Q3 24 | — | $-24.0M | ||
| Q2 24 | — | $-8.3M |
毛利率ASPIVSTM
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
营业利润率ASPIVSTM
| Q4 25 | — | — | ||
| Q3 25 | -306.1% | -362.2% | ||
| Q2 25 | — | -2047.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -182.8% |
净利率ASPIVSTM
| Q4 25 | — | — | ||
| Q3 25 | -263.7% | -876.3% | ||
| Q2 25 | — | -1213.6% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -82.6% |
每股收益（稀释后）ASPIVSTM
| Q4 25 | — | — | ||
| Q3 25 | $-0.15 | $-1.35 | ||
| Q2 25 | — | $-0.62 | ||
| Q3 24 | — | $-0.60 | ||
| Q2 24 | — | $-0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $137.7M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $-15.5M |
| 总资产 | $498.0M | $176.9M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPIVSTM
| Q4 25 | $333.3M | — | ||
| Q3 25 | $113.9M | $137.7M | ||
| Q2 25 | — | $164.3M | ||
| Q3 24 | — | $113.2M | ||
| Q2 24 | — | $83.4M |
总债务ASPIVSTM
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | $40.5M | ||
| Q2 24 | — | $40.3M |
股东权益ASPIVSTM
| Q4 25 | $204.2M | — | ||
| Q3 25 | $74.1M | $-15.5M | ||
| Q2 25 | — | $36.1M | ||
| Q3 24 | — | $11.1M | ||
| Q2 24 | — | $18.9M |
总资产ASPIVSTM
| Q4 25 | $498.0M | — | ||
| Q3 25 | $225.9M | $176.9M | ||
| Q2 25 | — | $196.3M | ||
| Q3 24 | — | $126.4M | ||
| Q2 24 | — | $105.7M |
负债/权益比ASPIVSTM
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | 3.66× | ||
| Q2 24 | — | 2.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-36.2M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | — |
| 自由现金流率自由现金流/营收 | -284.7% | — |
| 资本支出强度资本支出/营收 | 57.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASPIVSTM
| Q4 25 | $-37.8M | — | ||
| Q3 25 | $-8.9M | $-36.2M | ||
| Q2 25 | — | $-32.7M | ||
| Q3 24 | — | $-23.8M | ||
| Q2 24 | — | $-27.6M |
自由现金流ASPIVSTM
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-27.6M |
自由现金流率ASPIVSTM
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -275.8% |
资本支出强度ASPIVSTM
| Q4 25 | 57.9% | — | ||
| Q3 25 | 64.4% | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
